{"id":"diethylcarbamazine","rwe":[{"pmid":"41817502","year":"2026","title":"Cost-Effectiveness of Triple Versus Dual-Drug Therapy for Elimination of Lymphatic Filariasis in India.","finding":"","journal":"Value in health regional issues","studyType":"Clinical Study"},{"pmid":"41727130","year":"2026","title":"Deep phenotypic profiling uncovers cryptic effects of antifilarial drugs.","finding":"","journal":"bioRxiv : the preprint server for biology","studyType":"Clinical Study"},{"pmid":"41632749","year":"2026","title":"The Death to Onchocerciasis and Lymphatic Filariasis (DOLF) project: Accomplishments and ongoing research.","finding":"","journal":"PLoS neglected tropical diseases","studyType":"Clinical Study"},{"pmid":"41498296","year":"2026","title":"Ocular filariasis manifesting as an orbital cellulitis and conjunctival nodule: a case report.","finding":"","journal":"Orbit (Amsterdam, Netherlands)","studyType":"Clinical Study"},{"pmid":"41486614","year":"2026","title":"Diethylcarbamazine reduces the viral titer of influenza A (H1N1)pdm09 virus and regulates IFN-β and IL-8 in infected epithelial cells.","finding":"","journal":"Immunopharmacology and immunotoxicology","studyType":"Clinical Study"}],"tags":[{"label":"Anthelmintic","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Arachidonate 5-lipoxygenase","category":"target"},{"label":"ALOX5","category":"gene"},{"label":"PTGS1","category":"gene"},{"label":"P02CB02","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Bancroft's Filariasis","category":"indication"},{"label":"Eosinophilic asthma","category":"indication"},{"label":"Infection by Loa loa","category":"indication"},{"label":"Infection by Onchocerca volvulus","category":"indication"},{"label":"Lymphatic filariasis","category":"indication"},{"label":"Lederle","category":"company"},{"label":"Approved 1950s","category":"decade"},{"label":"Anthelmintics","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antinematodal Agents","category":"pharmacology"},{"label":"Antiparasitic Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Filaricides","category":"pharmacology"},{"label":"Lipoxygenase Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DIETHYLCARBAMAZINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:40:59.069838+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:41:07.690100+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DIETHYLCARBAMAZINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:41:08.340257+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL684/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:41:08.959239+00:00"}},"allNames":"caricide","offLabel":[],"synonyms":["diethylcarbamazine citrate","diethylcarbamazine","carbamazine","carbilazine","bitirazine","caricide","ethodryl","notezine"],"timeline":[{"date":"1950-11-13","type":"positive","source":"DrugCentral","milestone":"FDA approval (Lederle)"}],"aiSummary":"Caricide (Diethylcarbamazine) is a small molecule anthelmintic drug developed by Lederle, targeting Arachidonate 5-lipoxygenase. It is FDA-approved for treating various filarial infections, eosinophilic asthma, and infections caused by Loa loa and Onchocerca volvulus. As an off-patent medication, Caricide is not commercially available as a generic version. Key safety considerations include potential allergic reactions and exacerbation of certain conditions. Caricide has been approved since 1950 and is currently owned by Lederle.","approvals":[{"date":"1950-11-13","orphan":false,"company":"LEDERLE","regulator":"FDA"}],"brandName":"Caricide","ecosystem":[{"indication":"Bancroft's Filariasis","otherDrugs":[],"globalPrevalence":null},{"indication":"Eosinophilic asthma","otherDrugs":[{"name":"benralizumab","slug":"benralizumab","company":"Astrazeneca Ab"},{"name":"mepolizumab","slug":"mepolizumab","company":"Glaxosmithkline Llc"},{"name":"prednisolone","slug":"prednisolone","company":""},{"name":"reslizumab","slug":"reslizumab","company":"Teva Respiratory Llc"}],"globalPrevalence":262000000},{"indication":"Infection by Loa loa","otherDrugs":[],"globalPrevalence":null},{"indication":"Infection by Onchocerca volvulus","otherDrugs":[{"name":"ivermectin","slug":"ivermectin","company":"Merck Sharp Dohme"},{"name":"moxidectin","slug":"moxidectin","company":"Mdgh"}],"globalPrevalence":null},{"indication":"Lymphatic filariasis","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Arachidonate 5-lipoxygenase","novelty":"Follow-on","targets":[{"gene":"ALOX5","source":"DrugCentral","target":"Arachidonate 5-lipoxygenase","protein":"Arachidonate 5-lipoxygenase"},{"gene":"PTGS1","source":"DrugCentral","target":"Prostaglandin G/H synthase 1","protein":"Prostaglandin G/H synthase 1"}],"modality":"Small Molecule","drugClass":"Anthelmintic","explanation":"","oneSentence":"","technicalDetail":"Caricide specifically targets the enzyme Arachidonate 5-lipoxygenase, which is involved in the biosynthesis of leukotrienes, potent inflammatory mediators. By inhibiting this enzyme, Caricide reduces the production of leukotrienes, thereby alleviating symptoms associated with parasitic infections."},"commercial":{"launchDate":"1950","_launchSource":"DrugCentral (FDA 1950-11-13, LEDERLE)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/873","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=DIETHYLCARBAMAZINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DIETHYLCARBAMAZINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T10:41:22.332044","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:41:10.968130+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"piperazine","drugSlug":"piperazine","fdaApproval":"1954-07-12","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"diethylcarbamazine","indications":{"approved":[{"name":"Bancroft's Filariasis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Eosinophilic asthma","source":"DrugCentral","snomedId":367542003,"regulator":"FDA","usPrevalence":25000000,"globalPrevalence":262000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"},{"name":"Infection by Loa loa","source":"DrugCentral","snomedId":44250009,"regulator":"FDA"},{"name":"Infection by Onchocerca volvulus","source":"DrugCentral","snomedId":38539003,"regulator":"FDA"},{"name":"Lymphatic filariasis","source":"DrugCentral","snomedId":240820001,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"piperazine","brandName":"piperazine","genericName":"piperazine","approvalYear":"1954","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT00001230","phase":"","title":"Host Response to Infection and Treatment in Filarial Diseases","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1991-03-15","conditions":["Filariasis","Helminthiasis","Parasitic Infection","Mansonelliasis","Onchocerciasis"],"enrollment":500,"completionDate":""},{"nctId":"NCT04410406","phase":"PHASE3","title":"Moxidectin for LF, Cote d'Ivoire (DOLF)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2020-08-20","conditions":["Lymphatic Filariasis"],"enrollment":164,"completionDate":"2024-10-01"},{"nctId":"NCT06070116","phase":"PHASE2","title":"Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-04-05","conditions":["Onchocercal Subcutaneous Nodule","Onchocerciasis","Onchocerciasis, Ocular","Onchocerca Infection","Tropical Disease"],"enrollment":300,"completionDate":"2026-09-01"},{"nctId":"NCT07159373","phase":"PHASE3","title":"Better Options for Lymphatic Filariasis Treatment","status":"NOT_YET_RECRUITING","sponsor":"Medicines Development for Global Health","startDate":"2026-03","conditions":["Lymphatic Filariasis","Scabies","Strongyloidiasis"],"enrollment":5100,"completionDate":"2028-06"},{"nctId":"NCT04035174","phase":"NA","title":"Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa","status":"WITHDRAWN","sponsor":"Center for Research on Filariasis and Other Tropical Diseases, Cameroon","startDate":"2022-09-01","conditions":["Onchocerciasis","Loiasis","Diagnoses Disease","Neglected Diseases"],"enrollment":0,"completionDate":"2023-03-30"},{"nctId":"NCT04188301","phase":"PHASE2","title":"Safety and Efficacy of IDA for Onchocerciasis","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-12-06","conditions":["Onchocerciasis"],"enrollment":154,"completionDate":"2022-06-01"},{"nctId":"NCT02644525","phase":"PHASE2","title":"Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-09-16","conditions":["Loiasis"],"enrollment":20,"completionDate":"2021-03-19"},{"nctId":"NCT02974049","phase":"NA","title":"Lymphatic Filariasis (LF) in Ivory Coast","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2015-01","conditions":["Lymphatic Filariasis"],"enrollment":189,"completionDate":"2018-09-25"},{"nctId":"NCT01111305","phase":"PHASE2","title":"Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-04","conditions":["Loiasis"],"enrollment":31,"completionDate":"2017-09"},{"nctId":"NCT02899936","phase":"NA","title":"Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2016-07","conditions":["Lymphatic Filariasis"],"enrollment":23789,"completionDate":"2018-05-31"},{"nctId":"NCT03352206","phase":"","title":"Prevalence Studies After Triple Drug Therapy for Lymphatic Filariasis","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-10-18","conditions":["Lymphatic Filariases"],"enrollment":20092,"completionDate":"2019-11-01"},{"nctId":"NCT03177993","phase":"NA","title":"Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-07-13","conditions":["Lymphatic Filariases","Scabies","Impetigo","Soil Transmitted Helminths"],"enrollment":4773,"completionDate":"2019-10-24"},{"nctId":"NCT01905423","phase":"","title":"Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2011-05","conditions":["Lymphatic Filariasis","Soil Transmitted Helminth Infections"],"enrollment":17108,"completionDate":"2015-12"},{"nctId":"NCT00342576","phase":"","title":"Host Response to Infection and Treatment in Lymphatic Filarial Disease in India","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1994-04-23","conditions":["Lymphatic Filarial Disease"],"enrollment":1500,"completionDate":"2019-07-15"},{"nctId":"NCT02845713","phase":"PHASE1","title":"Pharmacokinetics & Pharmacodynamics of Diethylcarbamazine (DEC)+ Albendazole (ALB) + Ivermectin (IVE)","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2016-04-17","conditions":["Wuchereria Bancrofti Infection"],"enrollment":66,"completionDate":"2016-06-04"},{"nctId":"NCT03268252","phase":"","title":"Optimization of MDA With Existing Drug Regimens for LF: Monitoring Efficacy of Ongoing Treatment Programs in PNG","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2012-06","conditions":["Lymphatic Filariasis"],"enrollment":3200,"completionDate":"2018-12"},{"nctId":"NCT03676140","phase":"PHASE3","title":"Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )","status":"COMPLETED","sponsor":"Lihir Medical Centre","startDate":"2018-10-01","conditions":["Trachoma","Yaws","Lymphatic Filariases","Scabies","Strongyloidiasis"],"enrollment":20000,"completionDate":"2019-01-01"},{"nctId":"NCT03664063","phase":"PHASE2","title":"PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )","status":"COMPLETED","sponsor":"Lihir Medical Centre","startDate":"2018-09-01","conditions":["Lymphatic Filariasis","Yaws","Trauma"],"enrollment":42,"completionDate":"2019-01-01"},{"nctId":"NCT01975441","phase":"PHASE2","title":"Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa","status":"COMPLETED","sponsor":"University Hospitals Cleveland Medical Center","startDate":"2014-05","conditions":["Lymphatic Filariasis"],"enrollment":182,"completionDate":"2018-06"},{"nctId":"NCT00375583","phase":"PHASE2","title":"Effect of Albendazole Dose on Clearance of Filarial Worms","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-09-09","conditions":["Lymphatic Filariasis","Wuchereria Bancrofti Infection"],"enrollment":1000,"completionDate":"2011-04-28"},{"nctId":"NCT00344279","phase":"","title":"Changes in HIV Viral Load in Patients Undergoing Treatment for Filariasis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-08-08","conditions":["Filarial Infection","HIV Infections"],"enrollment":1000,"completionDate":"2012-01-31"},{"nctId":"NCT01593722","phase":"PHASE4","title":"Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-04","conditions":["Loiasis"],"enrollment":155,"completionDate":"2014-01"},{"nctId":"NCT00511004","phase":"PHASE2","title":"Effect of Albendazole Dose on Treatment of Lymphatic Filariasis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-07","conditions":["Lymphatic Filariasis"],"enrollment":40,"completionDate":"2014-02"},{"nctId":"NCT02005653","phase":"PHASE4","title":"Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection","status":"COMPLETED","sponsor":"Indian Council of Medical Research","startDate":"2009-02","conditions":["Filarial; Infestation"],"enrollment":146,"completionDate":"2013-08"},{"nctId":"NCT00295698","phase":"NA","title":"Interaction Between HIV and Lymphatic Filariasis","status":"COMPLETED","sponsor":"DBL -Institute for Health Research and Development","startDate":"2001-08","conditions":["HIV Infection","Lymphatic Filariasis"],"enrollment":0,"completionDate":"2002-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NDDF":"002970","UNII":"V867Q8X3ZD","CHEBI":"CHEBI:4527","INN_ID":"1540","RXNORM":"203175","UMLSCUI":"C0012191","chemblId":"CHEMBL684","ChEMBL_ID":"CHEMBL684","KEGG_DRUG":"D00803","DRUGBANK_ID":"DB00711","PUBCHEM_CID":"3052","SNOMEDCT_US":"1197375009","SECONDARY_CAS_RN":"1642-54-2","MESH_DESCRIPTOR_UI":"D004049"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1950-","companyName":"Lederle","relationship":"Original Developer"}],"publicationCount":1778,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"P02CB02","allCodes":["P02CB02"]},"biosimilarFilings":[],"originalDeveloper":"Lederle","recentPublications":[{"date":"2026 Mar 12","pmid":"41817502","title":"Cost-Effectiveness of Triple Versus Dual-Drug Therapy for Elimination of Lymphatic Filariasis in India.","journal":"Value in health regional issues"},{"date":"2026 Feb 13","pmid":"41727130","title":"Deep phenotypic profiling uncovers cryptic effects of antifilarial drugs.","journal":"bioRxiv : the preprint server for biology"},{"date":"2026 Feb","pmid":"41632749","title":"The Death to Onchocerciasis and Lymphatic Filariasis (DOLF) project: Accomplishments and ongoing research.","journal":"PLoS neglected tropical diseases"},{"date":"2026 Jan 7","pmid":"41498296","title":"Ocular filariasis manifesting as an orbital cellulitis and conjunctival nodule: a case report.","journal":"Orbit (Amsterdam, Netherlands)"},{"date":"2026 Feb","pmid":"41486614","title":"Diethylcarbamazine reduces the viral titer of influenza A (H1N1)pdm09 virus and regulates IFN-β and IL-8 in infected epithelial cells.","journal":"Immunopharmacology and immunotoxicology"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"1950","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1950-11-13T00:00:00.000Z","mah":"LEDERLE","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:41:10.968130+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}